Showalter; Howard Daniel Hollis

Patent Applications and Registrations

Patent applications and USPTO patent grants for Showalter; Howard Daniel Hollis.The latest application filed is for "pteridinones as kinase inhibitors".

Company Profile

0.15.8

Showalter; Howard Daniel Hollis - Ann Arbor MI

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pyrimido[5,4-d]pyrimidines derivatives as irreversible inhibitors of tyrosine kinases Grant 7,786,131 - Bridges , et al. August 31, 2	2010-08-31
3-aminoquinazolin-2,4-dione antibacterial agents Grant 7,582,627 - Bird , et al. September 1, 2	2009-09-01
Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation Grant 7,501,425 - Dobrusin , et al. March 10, 2	2009-03-10
Pteridinones As Kinase Inhibitors App 20070049600 - Denny; William Alexander ; et al.	2007-03-01
Pteridinones as kinase inhibitors Grant 7,169,778 - Denny , et al. January 30, 2	2007-01-30
3-Aminoquinazolin-2,4-dione antibacterial agents App 20060287308 - Bird; Paul ; et al.	2006-12-21
3-aminoquinazolin-2,4-dione antibacterial agents Grant 7,094,780 - Bird , et al. August 22, 2	2006-08-22
3-aminoquinazolin-2,4-dione Antibacterial Agents App 20060183762 - Bird; Paul ; et al.	2006-08-17
Antibacterial agents Grant 6,864,259 - Ellsworth , et al. March 8, 2	2005-03-08
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation App 20040044012 - Dobrusin, Ellen Myra ; et al.	2004-03-04
Pyridotriazines and pyridopyridazines Grant 6,683,183 - Kramer , et al. January 27, 2	2004-01-27
Irreversible inhibitors of tyrosine kinases Grant 6,602,863 - Bridges , et al. August 5, 2	2003-08-05
Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family Grant 6,596,726 - Bridges , et al. July 22, 2	2003-07-22
Pteridinones as kinase inhibitors App 20030130286 - Denny, William Alexander ; et al.	2003-07-10
Antibacterial agents App 20030114458 - Ellsworth, Edmund Lee ; et al.	2003-06-19
Antibacterial agents App 20030114666 - Ellsworth, Edmund Lee ; et al.	2003-06-19
Pyridotriazines and pyridopyridazines App 20020061865 - Kramer, James Bernard ; et al.	2002-05-23
Irreversible inhibitors of tyrosine kinases Grant 6,344,459 - Bridges , et al. Fe	2002-02-05
Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation Grant 6,218,388 - Boschelli , et al. April 17, 2	2001-04-17
Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation Grant 5,990,146 - Boschelli , et al. November 23, 1	1999-11-23
6-aryl naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation Grant 5,952,342 - Blankley , et al. September 14, 1	1999-09-14
6-Aryl pyrido[2,3-d] pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation Grant 5,733,913 - Blankley , et al. March 31, 1	1998-03-31
Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family Grant 5,679,683 - Bridges , et al. Oc	1997-10-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.